There is a new option for cancer treatment: more and more international patients are choosing to receive CAR-T cell therapy in China, where the cost is only about one-fifth of comparable treatment in the US, while clinical efficacy is equally recognized internationally. This combination of price and efficacy is reshaping the landscape of cross-border cancer treatment.
Cost comparison
In the US, a single course of CAR-T therapy typically costs US$400,000-500,000, excluding additional expenses such as hospitalization and complication management. In China, with multiple CAR-T products approved and gradually entering medical insurance negotiations, the actual burden on patients has dropped significantly, with total treatment costs roughly one-fifth of US levels, including more complete inpatient and follow-up management.
Efficacy and safety
Clinical data from China's CAR-T programs show excellent results in relapsed/refractory lymphoma and multiple myeloma, with long-term follow-up showing sustained remission in a significant proportion of patients. Multiple top-tier hematology-oncology centers in Shanghai have mature full-process CAR-T management capability, from cell collection and manufacturing to post-infusion adverse event management.
Why choose China
Beyond the cost advantage, CAR-T treatment in China also features: high product accessibility with multiple approved drugs; experienced clinical centers with standardized full-process management; and complete supporting services covering interpretation, accommodation and follow-up.
How international patients can arrange
Patients planning CAR-T treatment in China should submit medical records for preliminary evaluation in advance, confirm indications through remote consultation, then arrange travel to Shanghai. MedBridge can assist with medical record pre-review, expert matching, cost estimation and full coordination.